Literature DB >> 2276986

A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains.

S A Howell1, A I Mallet, W C Noble.   

Abstract

The mechanism of azole resistance of Candida albicans NCPF 3310 (the deposited culture of the Darlington strain) has been investigated but never fully explained. Seven isolates of this strain, from various sources, were examined by gas chromatography-mass spectrometry to detect changes in the sterol composition following passage through many laboratories over several years. Five of the seven, including one recently isolated from the patient, were found to be similar to each other in sterol content, containing large amounts of fecosterol. Of the remaining two, one was thought to be a sensitive variant, both produced only small quantities of fecosterol and resembled the normal clinical strains and other azole-resistant strains in sterol content. The sterol composition of the Darlington strain was unique and apparently stable to prolonged in vitro experimentation and passage through the patient.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276986     DOI: 10.1111/j.1365-2672.1990.tb01564.x

Source DB:  PubMed          Journal:  J Appl Bacteriol        ISSN: 0021-8847


  13 in total

1.  Restriction fragment length polymorphism analysis of azole-resistant and azole-susceptible Candida albicans strains.

Authors:  M A Pearce; S A Howell
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

2.  Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays.

Authors:  K Venkateswarlu; D W Denning; N J Manning; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 3.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

4.  Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia.

Authors:  F S Nolte; T Parkinson; D J Falconer; S Dix; J Williams; C Gilmore; R Geller; J R Wingard
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.

Authors:  G D Albertson; M Niimi; R D Cannon; H F Jenkinson
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Mechanisms of azole resistance in petite mutants of Candida glabrata.

Authors:  Sophie Brun; Thierry Bergès; Pascal Poupard; Carole Vauzelle-Moreau; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance.

Authors:  F S Clark; T Parkinson; C A Hitchcock; N A Gow
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility.

Authors:  A Geber; C A Hitchcock; J E Swartz; F S Pullen; K E Marsden; K J Kwon-Chung; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Characterization of an azole-resistant Candida glabrata isolate.

Authors:  H vanden Bossche; P Marichal; F C Odds; L Le Jeune; M C Coene
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.